Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion.[ Read More ]
The intrinsic value of one IXHL stock under the base case scenario is HIDDEN Compared to the current market price of 2 USD, Incannex Healthcare Limited is HIDDEN
Current Assets | 16.2 M |
Cash & Short-Term Investments | 5.86 M |
Receivables | 0 |
Other Current Assets | 10.3 M |
Non-Current Assets | 845 K |
Long-Term Investments | 0 |
PP&E | 845 K |
Other Non-Current Assets | 0 |
Current Liabilities | 5.62 M |
Accounts Payable | 527 K |
Short-Term Debt | 163 K |
Other Current Liabilities | 4.93 M |
Non-Current Liabilities | 210 K |
Long-Term Debt | 210 K |
Other Non-Current Liabilities | 0 |
Revenue | 12 K |
Cost Of Revenue | 0 |
Gross Profit | 12 K |
Operating Expenses | 30.1 M |
Operating Income | -30 M |
Other Expenses | -11.6 M |
Net Income | -18.5 M |
Net Income | -18.5 M |
Depreciation & Amortization | 103 K |
Capital Expenditures | -277 K |
Stock-Based Compensation | 8.93 M |
Change in Working Capital | -14.2 M |
Others | -6.42 M |
Free Cash Flow | -16.1 M |
Date | Value | Insider | Amount | Avg Price |
---|